These guys are never always right or never always wrong. Just like the rest of us.
They say VNDA changed the endpoints of the study without FDA permission therefore the Advisory panel will recommend a No approval.
If you read the transcript of qtr 2 conference call when this question was asked, VNDA management said they changed the endpoints based on a recommendation from the FDA.